A comprehensive new study which was published by the US Justice Department earlier this month found that the levels of THC – the most dominant psychoactive component of the cannabis plant – don’t function as reliable indicators for impaired driving.
According to the study's results, many of the participants had reported significantly decreased cognitive and psychomotor functioning even when their blood, urine and oral fluid contained low levels of THC.
The researchers also observed that standardized field sobriety tests – such as the one-leg stand, walk and turn, and modified Romberg balance tests – commonly used to detect driving under the influence of drugs or alcohol, were not effective tools for the detection of cannabis intoxication.
The study’s results complicate the enforcement of police laws against driving under the influence of cannabis and could essentially bury the so far quickly developing commercial field of THC testing kits.
One such test – “Drugwipe,” a saliva-based drug test which was developed by Securetek – was selected last month to go into official use after a years-long tender by Israel Police.
Drugwipe works similarly to a pregnancy test, giving police a yes or no answer regarding the existence of certain drug levels – in this case, an as-of-yet undetermined amount of THC – in a person’s saliva. If they test positive, they are sent to the police station to receive a more comprehensive blood test.
However, the results of the study seem to indicate that both tests could be completely unreliable factors in determining whether someone is capable of driving.
While the product can detect up to seven different kinds of drugs, its main intended use was for the detection of THC.
Now that the study essentially nullifies the main purpose of Securetek’s technology, the official importer chosen for the project, Dolphin Medical – an offshoot of the larger Shizim company, whose CEO is former Mossad chief Tamir Pardo – are looking to see whether Israel Police will indeed end up adding the product to their protocols.
PSYCHIATRIST PROF. Shaul Lev-Ran, Co-founder of the Israel Center on Addiction spoke with The Jerusalem Post on Monday to explain the likely reasons behind the study’s results.
Lev-Ran explained that while alcohol is one specific substance, allowing development of effective breathalyzers, cannabis is a complex plant composing of over 100 different cannabinoids and 400 different terpenes which make the development of similar breathalyzers substantially more complex.
Cannabis is also unique in that it does not leave the human bloodstream as quickly as other drugs, especially its relatives in the psychedelic family. While compounds like LSD and psilocybin normally leave the bloodstream within a day or two, heavy cannabis users can often find cannabis in their blood even a month after use.
“Right now, science doesn’t have an accurate way of measuring how long after cannabis consumption someone would need to wait before it is safe for them to drive again.”